Shi Si Pharmaceutical Group: Propranolol Hydrochloride has been approved by the China Food and Drug Administration for registration as an active pharmaceutical ingredient for use in marketed formulations.

ShiSi Pharmaceutical Group announces that its Propranolol Hydrochloride has been approved by the China National Medical Products Administration for registration as an active pharmaceutical ingredient in market formulations. Propranolol hydrochloride is mainly used for secondary prevention, reducing the mortality rate of myocardial infarction; hypertension; effort-induced angina pectoris; and controlling supraventricular tachycardia and ventricular arrhythmias.